期刊文献+

367例心房颤动住院病例病因与治疗分析 被引量:6

Analysis on pathogenesis and treatment for 367 patients with atrial fibrillation
在线阅读 下载PDF
导出
摘要 目的探讨心房颤动住院患者的病因和药物治疗情况。方法对2009年1月~2011年3月新疆医科大学第一附属医院住院的367例心房颤动患者的临床资料进行回顾性分析。结果各族别的引起房颤的病因中,汉族以高血压、冠心病为主,而哈萨克族以风湿性瓣膜病、高血压为主。高血压(P=0.022)、风湿性瓣膜病(P=0.000)、心肌病(P=0.022)在汉、哈萨克族房颤发生病因中有统计学意义。心室率控制药物以β受体阻滞剂、地高辛使用最多;本组患者85.23%接受抗血栓治疗,其中抗血小板方法(78.64%)最多。结论该地区房颤患者病因分组、药物服用与全国及国外相关资料趋势接近。风心病、冠心病、高血压病是心房颤动(atrial fibrillationAF)的主要病因。 Objective To explore the pathogeny and medical treatment of atrial fibrillation(AF).MethodsThe data of 367 cases with atrial fibrillation were analyzed retrospectively.ResultsAtrial fibrillation pathogenesis and related factors statistics are hypertension(47.0%),Coro-nary heart disease(52.9%),Rheumatic valvular disease(25.9%),Hyperthyro-idism(2.3%),Idiopathic AF(2.0%),Cardiomyopathy(10.3%),Diabetes(9.7%).For those reasons caused atrial fibrillation,Hypertention and Coronary heart disease were main reasons for Hans,Therheumatic valvular disease and Hypertension were main reasons for Kazaks,Ventricular rate control drugs Beta blockers and Digoxin were used most of the Ventricular rate control drugs.85.23% of these patients had anti-thrombosis treatment.85.23% of these patients had antiplatelet treatment.ConclusionPathogenesis and treatment were similar with the other populations of china.Rheumatic heart disease,coronary heart disease,hypertension were the main causes of atrial fibrillation.
出处 《新疆医科大学学报》 CAS 2011年第8期787-790,共4页 Journal of Xinjiang Medical University
基金 国家自然科学基金(81060017)
关键词 心房颤动 病因 治疗分析 民族 atrial fibrillation pathogenesis treatment analysis race
  • 相关文献

参考文献7

二级参考文献16

  • 1Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the
  • 2Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 2001,119(1 Suppl):8S-21S.
  • 3Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest, 2001,119(1 Suppl):108S-121S.
  • 4The stroke prevention in atrial fibrillation investigation. Bleeding during antithrombotic thearapy in patients with atrial fibrillation. Arch Intern Med, 1996, 156:409-416.
  • 5Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med, 1996,124:970-979.
  • 6Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med,1994,120:897-902.
  • 7Stroke prevention in atrial fibrillation investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation Ⅲ randomized clinic trial. Lan
  • 8Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of reccurrent venous thromboembolism. N Engl J Med, 2003,348:1425-1434.
  • 9Wolf PAS,Mitchell JB,Baker CS,et al.Impact of atrial fibrillation on mortality,stroke,and medical costs[J].Arch Intern Med,1998,158:229-234.
  • 10Furberg CD,Manolio TA,Gardin JM,et al.Rautaharju PM.Prevalence of atrial fibrillation in elderly subjects(the cardiovasular health study)[J].Am J Cardiol,1994,74:236-241.

共引文献1772

同被引文献29

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部